← Back to Clinical Trials
Recruiting NCT07157618

NCT07157618 Prospective Pathology Foundation Models

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07157618
Status Recruiting
Phase
Sponsor Nanfang Hospital, Southern Medical University
Condition Pancancer
Study Type OBSERVATIONAL
Enrollment 2,000 participants
Start Date 2025-08-28
Primary Completion 2028-07

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 75 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 2,000 participants in total. It began in 2025-08-28 with a primary completion date of 2028-07.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Histopathology remains the gold standard for disease diagnosis, yet faces challenges including pathologist shortages and diagnostic model limitations. This underscores the critical need to develop deep learning-based pathology foundation models integrating prospective imaging and clinical data. Such models would enhance diagnostic accuracy and efficiency, enabling tumor grading, histo-molecular classification, and intelligent chemotherapy guidance - ultimately optimizing clinical workflows. However, a critical gap remains: the absence of prospectively validated, pan-disease pathology foundation models. Developing clinically validated models is therefore imperative.

Eligibility Criteria

Inclusion Criteria: 1. Aged 18-75 years old. 2. Patients with complete pathological slides and clinical information. Exclusion Criteria: 1.Patients with missing data or specimens not meeting quality control requirements for analysis.

Contact & Investigator

Central Contact

Zhengyu Zhang

✉ zzyusmu@163.com

📞 +8613837365993

Principal Investigator

Li Liang

STUDY DIRECTOR

Nanfang Hospital, Southern Medical University

Frequently Asked Questions

Who can join the NCT07157618 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Pancancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07157618 currently recruiting?

Yes, NCT07157618 is actively recruiting participants. Contact the research team at zzyusmu@163.com for enrollment information.

Where is the NCT07157618 trial being conducted?

This trial is being conducted at Guangzhou, China, Jinan, China.

Who is sponsoring the NCT07157618 clinical trial?

NCT07157618 is sponsored by Nanfang Hospital, Southern Medical University. The principal investigator is Li Liang at Nanfang Hospital, Southern Medical University. The trial plans to enroll 2,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology